Fondaparinux Discontinuation Before Surgery

Standard Preoperative Timing

The American College of Cardiology recommends that fondaparinux should be stopped more than 36 hours before elective surgery to allow adequate clearance of anticoagulant effect 1, 2
The last injection of fondaparinux must be given more than 36 hours before surgery to allow adequate clearance of anticoagulant effect, based on fondaparinux's half-life of approximately 17 hours, requiring roughly 2 half-lives for sufficient drug elimination 1, 2, 3
For CABG specifically, the American College of Cardiology recommends discontinuing fondaparinux 24 hours before surgery and transitioning to unfractionated heparin 5, 3

For neuraxial procedures, fondaparinux requires a longer discontinuation period of more than 48 hours to achieve anti-Xa levels below the detection threshold before performing these high-risk procedures 1, 2
The target is to achieve anti-Xa levels below the detection threshold before performing neuraxial procedures, such as spinal or epidural anesthesia, to minimize the risk of spinal or epidural hematomas 1, 2

In patients with acute heparin-induced thrombocytopenia requiring surgery within 1 month of diagnosis, consider switching to shorter-acting agents, such as argatroban or bivalirudin, rather than using fondaparinux perioperatively 1, 2
Argatroban requires only 4 hours discontinuation and bivalirudin only 2 hours, providing safer perioperative management for high-risk patients 1, 2

Do not use the 24-hour discontinuation window recommended for CABG bridging protocols as a general rule, as this applies only when transitioning to unfractionated heparin for cardiac surgery 5, 3
Do not confuse fondaparinux timing with shorter-acting anticoagulants like enoxaparin or bivalirudin, as this can lead to inadequate anticoagulation or increased bleeding risk 6, 5, 3